Liver X receptor modulators: a review of recently patented compounds (2009 – 2012)

The Liver X Receptor Agonist GW3965 Improves Recovery from Mild Repetitive Traumatic Brain Injury in Mice Partly through Apolipoprotein E

(2013) Dhananjay R. Namjoshi et al.   PLoS One

A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis

(2012) Kristine Griffett et al.   ACS Chemical Biology

Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses

(2012) Nathanael J. Spann et al.   CELL

LXRα is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice

(2012) Cynthia Hong et al.   JOURNAL OF LIPID RESEARCH

Design, Synthesis, and Biological Evaluation of Novel Transrepression-Selective Liver X Receptor (LXR) Ligands with 5,11-Dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one Skeleton

(2012) Atsushi Aoyama et al.   JOURNAL OF MEDICINAL CHEMISTRY

Liver X receptor   protects dopaminergic neurons in a mouse model of Parkinson disease

(2012) Y.-b. Dai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits

(2011) Shoko Honzumi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Blazeispirol A from Agaricus blazei Fermentation Product Induces Cell Death in Human Hepatoma Hep 3B Cells through Caspase-Dependent and Caspase-Independent Pathways

(2011) Zheng-Yuan Su et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway

(2011) D. Guo et al.   Cancer Discovery

Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F1B hamsters

(2010) Rai Ajit K. Srivastava   ATHEROSCLEROSIS

Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists

(2010) John W. Ullrich et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression

(2010) Jonathan E. Feig et al.   JOURNAL OF CLINICAL INVESTIGATION

Non-redundant roles for LXR  and LXR  in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice

(2010) E. D. Bischoff et al.   JOURNAL OF LIPID RESEARCH

Identification of Phenylsulfone-Substituted Quinoxaline (WYE-672) as a Tissue Selective Liver X-receptor (LXR) Agonist

(2010) Baihua Hu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Tertiary Sulfonamides as Potent Liver X Receptor Antagonists

(2010) William J. Zuercher et al.   JOURNAL OF MEDICINAL CHEMISTRY

Liver X Receptor Agonist Treatment Ameliorates Amyloid Pathology and Memory Deficits Caused by High-Fat Diet in APP23 Mice

(2010) N. F. Fitz et al.   JOURNAL OF NEUROSCIENCE

Modulation of ABCA1 by an LXR Agonist Reduces Beta-Amyloid Levels and Improves Outcome after Traumatic Brain Injury

(2010) David J. Loane et al.   JOURNAL OF NEUROTRAUMA

Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists

(2009) Kazunori Motoshima et al.   BIOORGANIC & MEDICINAL CHEMISTRY

1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists

(2009) Jeremy M. Travins et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRβ and low blood–brain penetration

(2009) Baihua Hu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists

(2009) Robert R. Singhaus et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists

(2009) Ronald C. Bernotas et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein

(2009) Daniel R. Scoles et al.   GYNECOLOGIC ONCOLOGY

Apoptotic Cells Promote Their Own Clearance and Immune Tolerance through Activation of the Nuclear Receptor LXR

(2009) Noelia A-Gonzalez et al.   IMMUNITY

Liver X Receptor Agonists Augment Human Islet Function through Activation of Anaplerotic Pathways and Glycerolipid/Free Fatty Acid Cycling

(2009) Takeshi Ogihara et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants

(2009) Arie Katz et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Liver X receptor activation restores memory in aged AD mice without reducing amyloid

(2009) Tim Vanmierlo et al.   NEUROBIOLOGY OF AGING

LXR Signaling Couples Sterol Metabolism to Proliferation in the Acquired Immune Response

(2008) Steven J. Bensinger et al.   CELL

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms

(2008) Lars Verschuren et al.   JOURNAL OF LIPID RESEARCH

Structure-Guided Design ofN-Phenyl Tertiary Amines as Transrepression-Selective Liver X Receptor Modulators with Anti-Inflammatory Activity

(2008) Esther Y. Chao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antiatherosclerotic Effects of a Novel Synthetic Tissue-Selective Steroidal Liver X Receptor Agonist in Low-Density Lipoprotein Receptor-Deficient Mice

(2008) D. Peng et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

ApoE Promotes the Proteolytic Degradation of Aβ

(2008) Qingguang Jiang et al.   NEURON

Carboxylic acid based quinolines as liver X receptor modulators that have LXRβ receptor binding selectivity

(2007) Baihua Hu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS